Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (32)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Malkinson, A. M.
Right arrow Articles by Piazza, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malkinson, A. M.
Right arrow Articles by Piazza, G. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol 19, 1353-1356, Copyright © 1998 by Oxford University Press

ARTICLES

Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone)

AM Malkinson, KM Koski, LD Dwyer-Nield, PL Rice, N Rioux, A Castonguay, DJ Ahnen, H Thompson, R Pamukcu and GA Piazza
Department of Pharmaceutical Sciences, School of Pharmacy and Colorado Cancer Center, University of Colorado Health Sciences Center, Denver 80262, USA. al.malkinson@uchsc.edu

The sulfone derivative of the non-steroidal anti-inflammatory drug (NSAID), sulindac, has been reported to inhibit mammary and colon tumor formation in rodent models of chemically-induced carcinogenesis. Unlike its parent compound, this metabolite lacks cyclo-oxygenase inhibitory activity. A tumor induction protocol, consisting of NNK administration in the drinking water over several weeks to model chronic human exposure, was used to test whether the sulfone (called FGN-1) could inhibit the formation of primary lung tumors in mice. A total of 150 female, AIN76A-fed, A/J mice received 9 mg of NNK each. Concentrations of FGN-1 that had been previously determined not to affect body weight gain were added to the food at levels of 0, 250, 500 and 750 mg/kg of diet (30 mice/group) starting 2 weeks before NNK administration and continuing for 22 weeks. At that time pleural surface tumors were counted. Tumor incidence decreased significantly from 96 % in the control diet and 93% in the 250 FGN-1 mg/kg diet to 63 and 67% in the 500 and 750 mg FGN-1/kg diet groups, respectively (P < 0.001 by chi- square analysis). Lung tumor multiplicity decreased from 18.1+/-3 tumors/ mouse (mean+/-SEM, control diet) to 12.3+/-3 (250), 5.3+/-1 (500) and 2.1+/-1 (750) (P < 0.0005 by post hoc ANOVA). In previous studies using this carcinogenesis protocol, the maximum tolerated dose of sulindac inhibited lung tumor multiplicity by no more than 50% with no effect on incidence. This dose-dependent reduction in tumorigenesis by a non-toxic dose of FGN-1 indicates a strong chemopreventive activity against experimental induction of lung carcinogenesis. The greater potency of the sulfone over sulindac and its lack of toxic side effects because of its inability to affect cyclo-oxygenase activity suggests that clinical testing in individuals at high risk for lung cancer should be considered.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
G. A. Piazza, A. B. Keeton, H. N. Tinsley, B. D. Gary, J. D. Whitt, B. Mathew, J. Thaiparambil, L. Coward, G. Gorman, Y. Li, et al.
A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor Activity
Cancer Prevention Research, June 1, 2009; 2(6): 572 - 580.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. E. Witta, D. L. Gustafson, A. S. Pierson, A. Menter, S. N. Holden, M. Basche, M. Persky, C. L. O'Bryant, C. Zeng, A. Baron, et al.
A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors
Clin. Cancer Res., November 1, 2004; 10(21): 7229 - 7237.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. K. Bauer, A. M. Malkinson, and S. R. Kleeberger
Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities
Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L685 - L703.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. R. Kisley, B. S. Barrett, A. K. Bauer, L. D. Dwyer-Nield, B. Barthel, A. M. Meyer, D. C. Thompson, and A. M. Malkinson
Genetic Ablation of Inducible Nitric Oxide Synthase Decreases Mouse Lung Tumorigenesis
Cancer Res., December 1, 2002; 62(23): 6850 - 6856.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. R. Kisley, B. S. Barrett, L. D. Dwyer-Nield, A. K. Bauer, D. C. Thompson, and A. M. Malkinson
Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice
Carcinogenesis, October 1, 2002; 23(10): 1653 - 1660.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Sun, J. P. Stevenson, J. M. Gallo, M. Redlinger, D. Haller, K. Algazy, B. Giantonio, H. Alila, and P. J. O'Dwyer
Phase I and Pharmacokinetic Trial of the Proapoptotic Sulindac Analog CP-461 in Patients with Advanced Cancer
Clin. Cancer Res., October 1, 2002; 8(10): 3100 - 3104.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Hida, K.-i. Kozaki, H. Ito, O. Miyaishi, Y. Tatematsu, T. Suzuki, K. Matsuo, T. Sugiura, M. Ogawa, T. Takahashi, et al.
Significant Growth Inhibition of Human Lung Cancer Cells Both in Vitro and in Vivo by the Combined Use of a Selective Cyclooxygenase 2 Inhibitor, JTE-522, and Conventional Anticancer Agents
Clin. Cancer Res., July 1, 2002; 8(7): 2443 - 2447.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. C. Chan, K. A. Earle, T. L. M. Zhao, B. Helfrich, C. Zeng, A. Baron, C. M. Whitehead, G. Piazza, R. Pamukcu, W. J. Thompson, et al.
Exisulind in Combination with Docetaxel Inhibits Growth and Metastasis of Human Lung Cancer and Prolongs Survival in Athymic Nude Rats with Orthotopic Lung Tumors
Clin. Cancer Res., March 1, 2002; 8(3): 904 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. A. Piazza, W. J. Thompson, R. Pamukcu, H. W. Alila, C. M. Whitehead, L. Liu, J. R. Fetter, W. E. Gresh Jr., A. J. Klein-Szanto, D. R. Farnell, et al.
Exisulind, a Novel Proapoptotic Drug, Inhibits Rat Urinary Bladder Tumorigenesis
Cancer Res., May 1, 2001; 61(10): 3961 - 3968.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
P. L. Rice, R. J. Goldberg, E. C. Ray, L. J. Driggers, and D. J. Ahnen
Inhibition of Extracellular Signal-regulated Kinase 1/2 Phosphorylation and Induction of Apoptosis by Sulindac Metabolites
Cancer Res., February 1, 2001; 61(4): 1541 - 1547.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
W. J. Thompson, G. A. Piazza, H. Li, L. Liu, J. Fetter, B. Zhu, G. Sperl, D. Ahnen, and R. Pamukcu
Exisulind Induction of Apoptosis Involves Guanosine 3',5'-Cyclic Monophosphate Phosphodiesterase Inhibition, Protein Kinase G Activation, and Attenuated {beta}-Catenin
Cancer Res., July 1, 2000; 60(13): 3338 - 3342.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
T. Hida, K.-i. Kozaki, H. Muramatsu, A. Masuda, S. Shimizu, T. Mitsudomi, T. Sugiura, M. Ogawa, and T. Takahashi
Cyclooxygenase-2 Inhibitor Induces Apoptosis and Enhances Cytotoxicity of Various Anticancer Agents in Non-Small Cell Lung Cancer Cell Lines
Clin. Cancer Res., May 1, 2000; 6(5): 2006 - 2011.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. F. Soriano, B. Helfrich, D. C. Chan, L. E. Heasley, P. A. Bunn Jr., and T.-C. Chou
Synergistic Effects of New Chemopreventive Agents and Conventional Cytotoxic Agents against Human Lung Cancer Cell Lines
Cancer Res., December 1, 1999; 59(24): 6178 - 6184.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. B.J. Smith, A. Castonguay, P. J. Donnelly, K. R. Reid, D. Petsikas, and T. E. Massey
Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells
Carcinogenesis, September 1, 1999; 20(9): 1809 - 1818.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Witschi, I. Espiritu, and D. Uyeminami
Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone
Carcinogenesis, July 1, 1999; 20(7): 1375 - 1378.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.